Clinical trials: Idiopathic Multicentric Castleman's Disease, active
Idiopathic Multicentric Castleman's Disease
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody …
- Trial name
- NCT05345522
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Beijing VDJBio Co., LTD.
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those…
- Trial name
- NCT07085039
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Anti IL-6R, Castleman's Disease, Multicentric
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to…
- Trial name
- NCT07872423
- Testing
- Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 8 sites in China
- Volunteers
- 45 people
- Sponsor
- Beijing VDJBio Co., LTD.